Form 8-K Aerovate Therapeutics, For: Jun 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TD Cowen Downgrades Aerovate Therapeutics Inc (AVTE) to Hold
June 17, 2024 4:06 PM EDTTD Cowen analyst Joseph Thome downgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Buy to Hold.
The analyst comments "Aerovate announced AV-101 did not achieve either the primary PVR endpoint or key secondary 6MWD endpoint for the Ph. IIb portion of the... More
Evercore ISI Downgrades Aerovate Therapeutics Inc (AVTE) to In Line
June 17, 2024 4:01 PM EDTEvercore ISI analyst Liisa Bayko downgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Outperform to In Line with a price target of $2.00 (from $27.00).
The analyst ocmments "AV-101, inhaled form of imatinib, was an abject failure in PAH, showing no clinically relevant benefit on PVR... More
Jefferies Downgrades Aerovate Therapeutics Inc (AVTE) to Hold
June 17, 2024 12:15 PM EDTJefferies analyst Eun Yang downgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Buy to Hold with a price target of $2.00 (from $65.00).
The analyst comments "AVTE announced that the Phase IIB failed in PAH and that none of the 3 doses demonstrated a clinically meaningful improvement in PVR.... More
BTIG Downgrades Aerovate Therapeutics Inc (AVTE) to Neutral
June 17, 2024 10:39 AM EDTBTIG analyst Julian Harrison downgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Buy to Neutral.
The analyst comments "AV-101 did not separate from placebo on its primary endpoint in the Phase 2b portion of IMPAHCT. All doses of AV-101 failed to meet stat sig on PVR at... More
